Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company
focused on developing next-generation therapeutics to target
difficult-to-treat cancers, today announced four abstracts for four
different assets have been accepted for poster presentation at the
Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
to be held November 1-5, 2023, in San Diego.
“We look forward to presenting a
trial-in-progress poster for PYX-201, our first-in-class and
first-in-concept tumor stroma-targeting antibody-drug conjugate
(ADC), and we are gratified by the investigator interest and
enthusiasm for our Phase 1 trial,” said Lara S. Sullivan, M.D.,
President and Chief Executive Officer of Pyxis Oncology. “Pyxis
Oncology is proud to be a pioneer in stromal therapeutics, and in
our view, targeting the tumor stroma represents a promising new
approach to cancer therapy that is designed to damage the barrier
that protects, feeds and provides structure to the
tumor. PYX-201 employs a linker-payload combination that
demonstrated an acceptable safety profile and dose-dependent
anti-tumor activity in prior clinical trials. We continue to expect
to see preliminary data from this study, including biomarker
results and early signs of potential clinical activity, in early
2024.”
Dr. Sullivan continued, “Additionally, we are
proud of the progress our team has made in advancing PYX-106, a
fully human immunotherapy antibody candidate in development that
blocks the activity of Siglec-15, for which we will also be
presenting a trial-in-progress poster, reflecting our operational
progress. We are pleased to share the insights we have generated
through our pre-clinical work on PYX-102, our KLRG-1 antibody,
which was deprioritized in 2022 and is available for
licensing/collaboration, as well as sotigalimab or PYX-107, our
newly acquired CD40 agonist from Apexigen, acquired through the
close our acquisition as announced on August 23, 2023. We look
forward to further advancements in our clinical pipeline to support
our mission of addressing the most difficult-to-treat tumors for
our patients.”
Abstract titles are now available on the SITC
website. Posters will be made available on the Pyxis Oncology
website following presentations at the conference. Presentation
details are as follows; times noted are Pacific time:
Title: A First-in-Human Phase 1 Clinical
Study Evaluating Safety, Tolerability, Pharmacokinetics,
Pharmacodynamics and Efficacy of the EDB+FN targeting ADC PYX-201
in Participants with Advanced Solid TumorsPoster
Number: 762Session Date /
Time: Saturday, November 4, 9:00am to 8:30pm
Title: First-in-Human, Open-label,
Multicenter, Phase 1 Clinical Study to Evaluate the Safety,
Tolerability, Pharmacokinetics, and Pharmacodynamics of anti
Siglec-15 PYX-106 in Subjects with Advanced Solid
TumorsPoster Number: 756Session Date
/ Time: Saturday, November 4, 9:00am
to 8:30pm
Title: Neoadjuvant CD40 Agonism Remodels
the Tumor Immune Microenvironment in Locally Advanced
Esophageal/Gastroesophageal Junction CancerPoster
Number: 1361Session Date /
Time: Friday, November 3, 9:00am to 7:00pm; oral
presentation on Saturday, November 4 from 3:20pm to 4:45 pm
Title: PYX-102, an Anti-KLRG1 Antibody,
Enhances Cytotoxic Activity of CD8 T cells from PBMC and Human
Tumor Samples by Blocking the Interaction Between KLRG1 and
CadherinsPoster Number: 572Session
Date / Time: Saturday, November 4, 9:00am to
8:30pm
About Pyxis Oncology, Inc.Pyxis
Oncology, Inc. is a clinical-stage company focused on defeating
difficult-to-treat cancers. The company is efficiently building
next-generation therapeutics that hold the potential for mono and
combination therapies. Pyxis Oncology’s therapeutic candidates are
designed to directly kill tumor cells and to address the underlying
pathologies created by cancer that enable its uncontrollable
proliferation and immune evasion. Pyxis Oncology’s antibody-drug
conjugates (ADCs) and immuno-oncology (IO) programs employ novel
and emerging strategies to target a broad range of solid tumors
resistant to current standards of care. To learn more, visit
www.pyxisoncology.com or follow us on Twitter and LinkedIn.
Forward-Looking StatementsThis
press release contains forward-looking statements for the purposes
of the safe harbor provisions under The Private Securities
Litigation Reform Act of 1995 and other federal securities laws.
These statements are often identified by the use of words such as
“anticipate,” “believe,” “can,” “continue,” “could,” “estimate,”
“expect,” “intend,” “likely,” “may,” “might,” “objective,”
“ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “to
be,” “will,” “would,” or the negative or plural of these words, or
similar expressions or variations, although not all forward-looking
statements contain these words. We cannot assure you that the
events and circumstances reflected in the forward-looking
statements will be achieved or occur and actual results could
differ materially from those expressed or implied by these
forward-looking statements. Factors that could cause or contribute
to such differences include, but are not limited to, those
identified herein, and those discussed in the section titled “Risk
Factors” set forth in Part II, Item 1A. of the Company’s Annual
Report on Form 10-K filed with SEC on March 22,
2023, on Form10-Q filed with the SEC on August 11, 2023, and
in our other filings with the SEC. These risks are not
exhaustive. New risk factors emerge from time to time, and it is
not possible for our management to predict all risk factors, nor
can we assess the impact of all factors on our business or the
extent to which any factor, or combination of factors, may cause
actual results to differ materially from those contained in any
forward-looking statements. In addition, statements that “we
believe” and similar statements reflect our beliefs and opinions on
the relevant subject. These statements are based upon information
available to us as of the date hereof and while we believe such
information forms a reasonable basis for such statements, such
information may be limited or incomplete, and our statements should
not be read to indicate that we have conducted an exhaustive
inquiry into, or review of, all potentially available relevant
information. These statements are inherently uncertain, and
investors are cautioned not to unduly rely upon these statements.
Except as required by law, we undertake no obligation to update any
forward-looking statements to reflect events or circumstances after
the date of such statements.
Pyxis Oncology ContactJennifer
Davis RuffVP, Investor Relationsjdavisruff@pyxisoncology.com
Pyxis Oncology (NASDAQ:PYXS)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Pyxis Oncology (NASDAQ:PYXS)
Historical Stock Chart
Von Jun 2023 bis Jun 2024